Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ex Vivo Comparison Of Combination Versus Single Therapeutic Pathway Inhibition In Human Intestinal Mucosa From Patients With Inflammatory Bowel Disease

NCT07824726 is registered in ClinicalTrials.gov with PhoenixLAB srls as lead sponsor.

NCT NCT07824726
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07824726 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ex Vivo Comparison Of Combination Versus Single Therapeutic Pathway Inhibition In Human Intestinal Mucosa From Patients With Inflammatory Bowel Disease
Lead sponsor
PhoenixLAB srls
Phase
Not applicable
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
October 1, 2026
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease (cd), ibd (inflammatory bowel disease), ulcerative colitis (uc)